The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company’s share price has tumbled some 60% over ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals. The news jolted the health care sector, which fell by 2.74% over the past ...

Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to ...

Hyderabad: Sales of weight-loss drugs Wegovy by Danish pharmaceutical giant Novo Nordisk and Mounjaro by U.S.-based Eli Lilly ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Denmark's status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

European shares posted their biggest weekly gain in twelve weeks on Friday, as banking stocks continued to drive the ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...